Tianlun Zhou, MD/PhD
Tianlun has been involved in antiviral research and drug discovery for more than 20 years. Currently, he serves as a professor at the Dept. of Translational Medicine, Baruch S. Blumberg Institute, Pennsylvania, USA. His research interest focuses on hepatitis B virus (HBV) RNA metabolism and mechanism of action studies of newly discovered antiviral compounds. During the years 2007 through 2015, Tianlun worked in Novartis China and was responsible for the development of novel in vitro assays to characterize product activity and safety. He directed liver cancer epidemiology studies in China and designed patient stratification strategies for precision treatment. He also supervised an international team for anti-HBV high throughput screen, hit validation and lead optimization in Novartis China. Prior to Novartis, Tianlun was a principal scientist in Nucleonics Inc., USA. He directed RNAi-based therapeutic development for HBV infection. The lead product was advanced to Phase-I clinical studies; first-in-class and first-in-human. Tianlun received his MD from Shanghai Medical University and PhD in Pathology form University of Pennsylvania.